ES2932049T3 - Compuestos heterocíclicos para el tratamiento de enfermedades - Google Patents
Compuestos heterocíclicos para el tratamiento de enfermedades Download PDFInfo
- Publication number
- ES2932049T3 ES2932049T3 ES16865156T ES16865156T ES2932049T3 ES 2932049 T3 ES2932049 T3 ES 2932049T3 ES 16865156 T ES16865156 T ES 16865156T ES 16865156 T ES16865156 T ES 16865156T ES 2932049 T3 ES2932049 T3 ES 2932049T3
- Authority
- ES
- Spain
- Prior art keywords
- optionally substituted
- compound
- alkyl
- group
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/433—Thidiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562255041P | 2015-11-13 | 2015-11-13 | |
| PCT/US2016/061676 WO2017083756A1 (en) | 2015-11-13 | 2016-11-11 | Heterocyclic compounds for the treatment of disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2932049T3 true ES2932049T3 (es) | 2023-01-09 |
Family
ID=58696139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16865156T Active ES2932049T3 (es) | 2015-11-13 | 2016-11-11 | Compuestos heterocíclicos para el tratamiento de enfermedades |
Country Status (22)
| Country | Link |
|---|---|
| US (5) | US10683291B2 (enExample) |
| EP (2) | EP4163281B1 (enExample) |
| JP (3) | JP6933384B2 (enExample) |
| KR (1) | KR102720397B1 (enExample) |
| CN (2) | CN114149424B (enExample) |
| AU (2) | AU2016353348A1 (enExample) |
| BR (1) | BR112018009745B1 (enExample) |
| CA (1) | CA3005236C (enExample) |
| DK (1) | DK3373931T3 (enExample) |
| ES (1) | ES2932049T3 (enExample) |
| HR (1) | HRP20221417T1 (enExample) |
| HU (1) | HUE060594T2 (enExample) |
| IL (1) | IL259297B2 (enExample) |
| LT (1) | LT3373931T (enExample) |
| MX (1) | MX382092B (enExample) |
| PL (1) | PL3373931T3 (enExample) |
| PT (1) | PT3373931T (enExample) |
| RS (1) | RS63837B1 (enExample) |
| RU (1) | RU2727194C2 (enExample) |
| SI (1) | SI3373931T1 (enExample) |
| SM (1) | SMT202300062T1 (enExample) |
| WO (1) | WO2017083756A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20221417T1 (hr) | 2015-11-13 | 2023-02-03 | Oppilan Pharma Ltd. | Heterociklički spojevi za liječenje bolesti |
| WO2018211323A1 (en) * | 2017-05-17 | 2018-11-22 | Oppilan Pharma Ltd. | Hetercyclic compounds for the treatment of disease |
| EP3625230A1 (en) * | 2017-05-17 | 2020-03-25 | Oppilan Pharma Ltd. | Prodrugs for the treatment of disease |
| GB201815018D0 (en) * | 2018-09-14 | 2018-10-31 | Univ Oxford Innovation Ltd | Enantiomeric compounds |
| US12612401B2 (en) | 2022-07-06 | 2026-04-28 | Oppilan Pharma Limited | Crystalline forms of an S1P receptor modulator |
| CN120835886A (zh) * | 2023-01-13 | 2025-10-24 | 奥比兰制药有限公司 | S1p受体调节剂的制备 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4772597A (en) * | 1983-10-14 | 1988-09-20 | Pfizer Inc. | 2-azacycloalkylthiopenem derivatives |
| WO2005032465A2 (en) | 2003-10-01 | 2005-04-14 | Merck & Co., Inc. | 3,5-aryl, heteroaryl or cycloalkyl substituted-1,2,4-oxadiazoles as s1p receptor agonists |
| GB0511684D0 (en) * | 2005-06-08 | 2005-07-13 | Novartis Ag | Organic compounds |
| US20080306124A1 (en) * | 2005-06-08 | 2008-12-11 | Rainer Albert | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands |
| RU2425832C2 (ru) * | 2006-04-03 | 2011-08-10 | Астеллас Фарма Инк. | Гетеросоединение |
| US20110207704A1 (en) | 2006-12-15 | 2011-08-25 | Abbott Laboratories | Novel Oxadiazole Compounds |
| RU2009127095A (ru) | 2006-12-15 | 2011-01-20 | Эбботт Лэборетриз (Us) | Новые оксадиазольные соединения |
| US20100160369A1 (en) * | 2008-12-04 | 2010-06-24 | Exelixis, Inc. | S1P1 Agonists and Methods of Making And Using |
| WO2010117662A1 (en) | 2009-03-30 | 2010-10-14 | Exelixis, Inc. | Modulators of s1p and methods of making and using |
| US9011494B2 (en) | 2009-09-24 | 2015-04-21 | Warsaw Orthopedic, Inc. | Composite vertebral rod system and methods of use |
| HUE036391T2 (hu) | 2009-11-13 | 2018-07-30 | Celgene Int Ii Sarl | Szfingozin 1 foszfát receptor modulátorok és királis szintézis eljárások |
| JP5788507B2 (ja) * | 2010-07-20 | 2015-09-30 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 置換３−フェニル−１，２，４−オキサジアゾール化合物 |
| US20140288052A1 (en) | 2011-10-20 | 2014-09-25 | GlaxoSmithKline, LLC | Substituted bicyclic aza-heterocycles and analogues as sirtuin modulators |
| JP6383418B2 (ja) | 2013-11-27 | 2018-08-29 | ジェネンテック， インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
| HRP20221417T1 (hr) | 2015-11-13 | 2023-02-03 | Oppilan Pharma Ltd. | Heterociklički spojevi za liječenje bolesti |
-
2016
- 2016-11-11 HR HRP20221417TT patent/HRP20221417T1/hr unknown
- 2016-11-11 RU RU2018121416A patent/RU2727194C2/ru active
- 2016-11-11 PL PL16865156.0T patent/PL3373931T3/pl unknown
- 2016-11-11 EP EP22195151.0A patent/EP4163281B1/en active Active
- 2016-11-11 WO PCT/US2016/061676 patent/WO2017083756A1/en not_active Ceased
- 2016-11-11 CA CA3005236A patent/CA3005236C/en active Active
- 2016-11-11 US US15/775,723 patent/US10683291B2/en active Active
- 2016-11-11 IL IL259297A patent/IL259297B2/en unknown
- 2016-11-11 PT PT168651560T patent/PT3373931T/pt unknown
- 2016-11-11 CN CN202111183182.7A patent/CN114149424B/zh active Active
- 2016-11-11 DK DK16865156.0T patent/DK3373931T3/da active
- 2016-11-11 LT LTEPPCT/US2016/061676T patent/LT3373931T/lt unknown
- 2016-11-11 KR KR1020187016508A patent/KR102720397B1/ko active Active
- 2016-11-11 EP EP16865156.0A patent/EP3373931B1/en active Active
- 2016-11-11 AU AU2016353348A patent/AU2016353348A1/en not_active Abandoned
- 2016-11-11 RS RS20221070A patent/RS63837B1/sr unknown
- 2016-11-11 HU HUE16865156A patent/HUE060594T2/hu unknown
- 2016-11-11 MX MX2018005987A patent/MX382092B/es unknown
- 2016-11-11 SM SM20230062T patent/SMT202300062T1/it unknown
- 2016-11-11 JP JP2018545102A patent/JP6933384B2/ja active Active
- 2016-11-11 CN CN201680078856.8A patent/CN108463222B/zh active Active
- 2016-11-11 SI SI201631650T patent/SI3373931T1/sl unknown
- 2016-11-11 BR BR112018009745-4A patent/BR112018009745B1/pt active IP Right Grant
- 2016-11-11 ES ES16865156T patent/ES2932049T3/es active Active
-
2020
- 2020-05-01 US US16/865,212 patent/US20200325135A1/en not_active Abandoned
-
2021
- 2021-05-10 AU AU2021202945A patent/AU2021202945B2/en active Active
- 2021-08-11 JP JP2021131351A patent/JP7174963B2/ja active Active
-
2022
- 2022-03-18 US US17/698,991 patent/US20220227767A1/en not_active Abandoned
- 2022-10-28 JP JP2022173717A patent/JP7445325B2/ja active Active
-
2023
- 2023-06-29 US US18/344,594 patent/US20230339944A1/en not_active Abandoned
-
2025
- 2025-05-14 US US19/207,818 patent/US20260092064A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260092064A1 (en) | Heterocyclic compounds for the treatment of disease | |
| JP2021502386A (ja) | Ａｓｈ１ｌ分解剤及びそれを用いた治療方法 | |
| ES2751642T3 (es) | Compuestos inhibidores de bromodominios y composición farmacéutica que los comprende para prevenir o tratar un cáncer | |
| CN105246887A (zh) | 香豆素衍生物以及用于治疗过度增生性疾病的方法 | |
| US20260132158A1 (en) | Phenyl oxy amide kinase inhibitors | |
| US20200046699A1 (en) | Compositions and methods for inhibiting kinases | |
| US20170190703A9 (en) | Organic compounds | |
| US20200071327A1 (en) | Prodrugs for the Treatment of Disease | |
| WO2018211323A1 (en) | Hetercyclic compounds for the treatment of disease | |
| HK40070316B (en) | Heterocyclic compounds for the treatment of disease | |
| HK40070316A (en) | Heterocyclic compounds for the treatment of disease | |
| US12528792B2 (en) | Sulfonamide compounds and the use thereof in the treatment of cancer | |
| HK1260375B (en) | Heterocyclic compounds for the treatment of disease | |
| HK1260375A1 (en) | Heterocyclic compounds for the treatment of disease | |
| CA3152424A1 (en) | Quinoline inhibitors of rad52 and methods of use |